Deutetrabenazine, marketed as Austedo, is a medication used to treat chorea associated with Huntington's disease and tardive dyskinesia [1][2]. It is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor [1].
How does deutetrabenazine work?
Deutetrabenazine works by reducing the amount of dopamine, a neurotransmitter, that is released in the brain. Dopamine plays a role in controlling movement, and an excess of it can lead to involuntary movements like chorea and tardive dyskinesia [1][2]. By inhibiting VMAT2, deutetrabenazine decreases the storage and release of monoamines, including dopamine, in the brain [1]. The deuterium atoms in deutetrabenazine replace hydrogen atoms, which slows down the drug's metabolism compared to its predecessor, tetrabenazine [3]. This slower metabolism may lead to a more predictable pharmacokinetic profile [3].
When can I expect AUSTEDO to be available?
AUSTEDO (deutetrabenazine) is an already approved and marketed medication. It is available by prescription [1][2].
What is the difference between Austedo and Austedo XR?
Austedo XR is an extended-release formulation of deutetrabenazine. Both medications are used to treat chorea associated with Huntington's disease and tardive dyskinesia. The XR version is designed to be taken once daily, whereas the immediate-release formulation of Austedo is typically taken twice daily [4].
What are the potential side effects of Austedo?
Common side effects of Austedo can include drowsiness, dry mouth, fatigue, insomnia, and depression [1]. A serious potential side effect is depression and suicidal thoughts or behaviors. Patients taking Austedo should be monitored for mood changes, and any new or worsening depression, anxiety, or suicidal thoughts should be reported to a healthcare provider immediately [1][5]. Other serious side effects may include Parkinsonism, QT interval prolongation, and hypersensitivity reactions [1].
How does deutetrabenazine compare to tetrabenazine?
Deutetrabenazine is a deuterated form of tetrabenazine. The key difference lies in the isotopic substitution of hydrogen with deuterium atoms. This substitution alters the drug's metabolic pathway, making it more stable and leading to a slower breakdown in the body. Consequently, deutetrabenazine offers a more consistent drug exposure compared to tetrabenazine, potentially allowing for less frequent dosing and a more predictable treatment response [3].
What is the patent status of deutetrabenazine?
Deutetrabenazine and its uses are protected by patents. DrugPatentWatch.com tracks patent information for pharmaceuticals, including deutetrabenazine [6]. Patent expiry dates are crucial for determining when generic versions of a drug can enter the market.
How much does Austedo cost?
The cost of Austedo can vary significantly depending on insurance coverage, pharmacy, and dosage. As a prescription medication, the price is subject to market dynamics and manufacturer pricing. Information regarding specific pricing may be available through the drug manufacturer's website or through pharmaceutical pricing resources [1][7].
What are the approved uses for deutetrabenazine?
Deutetrabenazine is approved for the treatment of chorea associated with Huntington's disease and tardive dyskinesia [1][2]. Huntington's disease is a progressive neurodegenerative disorder that affects movement, cognition, and behavior, often causing involuntary writhing movements known as chorea [8]. Tardive dyskinesia is a movement disorder that can occur as a side effect of certain medications, most commonly antipsychotics, characterized by involuntary, repetitive body movements [9].
Sources
1. Austedo Prescribing Information.
2. Austedo XR Prescribing Information.
3. FDA Approves Austedo (Deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington Disease
4. Deutetrabenazine Extended Release
5. Black Box Warning on Antidepressants
6. Deutetrabenazine Patents
7. Austedo Cost
8. Huntington's Disease Fact Sheet
9. Tardive Dyskinesia Information Page